Global Retinal Disease Therapeutics Market, By Disorder (Macular Degeneration, Diabetic Eye Disease, Retinal Detachment, Retinoblastoma, Macular Pucker, Macular Hole, Floaters), Disorder Type (Genetic, Age Related), Treatment Techniques (Laser, Freezing, Implanting, Indenting, Pneumatic Retinopexy, Scleral (SKLAIR-ul) Buckling, Vitrectomy), Route of Administration (Oral, Topical, Intravitreal, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Global retinal disease therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 9.0% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of the retinal disease therapeutics market.
Retina is a delicate layer of tissue located at the back end of the eyes and is responsible for light sensing and transferring images to brain, any form of retinal disorder may damage this delicate tissue and affect vision and in serious cases lead to blindness. Retinal disorders may be genetic or age related, causing degenerative changes in vision. A retinal examination is however the first step in diagnosis of the potential disease along with genetic testing for genetic retinal disorders.
Retinal disorders have both high prevalence and incidence in geriatric population as well as in diabetic’s patients, therefore rise in both adult and diabetic’s patient’s population will boost the retinal disease therapeutics market. Rise in R&D activities in developing countries are bound to boost the retinal disease therapeutics market growth globally as the prevalence of retinal disorder is increasing in both developed and developing countries. Rise in support offered by government and non-profitable organizations may have a positive impact on the global retinal disease therapeutics market. The presence of various pipeline products for retinal disorder treatment will also propel the global retinal disease therapeutics market to grow. High cost of retina treatment therapies as well as patient complaints as having experienced short-term side effects as well as long term complications as infection and inflammation after laser eye treatment may affect the global retinal disease therapeutics market growth. Also for surgical procedures as pneumatic retinopexy, certain complications as inadvertent scleral perforation may occur which may affect patient preferences constricting the global retinal disease therapeutics market growth. Also, low level of healthcare infrastructure in developing countries is bound to restrict the global retinal disease therapeutics market.
Increase in new product launches and ongoing clinical trials are acting as opportunities for the retinal disease therapeutics market to grow. Increasing advancements as gene therapy, functional prostheses and stem-cell therapy along with rising awareness about retinal diseases is an opportunity for the retinal disease therapeutics market to grow. In developed regions, the preventable cases of blindness are detected early and rise in eye routine check-ups and helping in robust healthcare system maintenance giving an opportunity to the global retinal disease therapeutics market to grow.
This retinal disease therapeutics market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the retinal disease therapeutics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Retinal Disease Therapeutics Market Scope and Market Size
The retinal disease therapeutics market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disorder, the retinal disease therapeutics market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters.
- On the basis of disorder type, the retinal disease therapeutics market is segmented into genetic and age-related.
- On the basis of treatment techniques, the retinal disease therapeutics market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral (sklair-ul) buckling, and vitrectomy.
- On the basis of route of administration, the retinal disease therapeutics market is segmented into oral, topical, intravitreal and others.
- On the basis of end-users, the retinal disease therapeutics market is segmented into hospitals, ambulatory surgical centres, home healthcare and others.
- On the basis of distribution channel, the retinal disease therapeutics market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Global Retinal Disease Therapeutics Market Country Level Analysis
Global retinal disease therapeutics market is analysed and market size information is provided by the country, disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.
The countries covered in the retinal disease therapeutics market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with majority of population have insurance cover to claim this type of expensive treatment.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The retinal disease therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to retinal disease therapeutics market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the retinal disease therapeutics market in the growth period.
Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis
The retinal disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to retinal disease therapeutics market.
The major players covered in the global retinal disease therapeutics market report are Santen Pharmaceutical Co. Ltd., Baush Health Companies Inc., Sentis Pharma Pvt Ltd., F. Hoffmann-L Roche Ltd, Johnson & Johnson Services, Inc., Novartis AG, Abbvie, Regeneron Pharmaceuticals, Inc., Akorn, Mitotech, SA, Kubota Pharmaceutical Holdings Co., Ltd., GRAYBUG VISION, INC., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Senju Pharmaceutical Co., Ltd., Valent Pharmaceuticals North America LLC, Genetech, Inc., Ocular Therapeutix, Teva Pharmaceutical Industries Ltd., Kala Pharmaceuticals, Eyevensys , Aldeyra Therapeutics, Inc. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Aldeyra Therapeutics, Inc. is focusing on developing and commercializing next generation medicines for improving patient compliance and living standards, announced acquisition of Helio Vision, Inc., this acquisition adds on to its product pipeline for an orphan drug designation named ADX-2191, intravitreal methotrexate for treatment of proliferative vitreoretinopathy which has no approved treatment and is still in Phase 3.